Breast Cancers Today
Advertisement
Dr Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
Study finds somatic differences and lower PI3K inhibitor use in Black vs White patients with metastatic breast cancer.
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends.
A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.
Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Researchers aimed to evaluate the roll of ERCC1 expression in predicting response to adjuvant chemotherapy for TNBC.
TILs can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who can reduce adjuvant therapy.
Cancer recurrence fear appreciably impacts breast cancer survivors’ ability to re-enter the workforce.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.